2023
Examining racial differences in smoking outcomes among smokers enrolled in an intravenous nicotine infusion study
Schwartz E, Palmisano A, Gueorguieva R, DeVito E, Sofuoglu M. Examining racial differences in smoking outcomes among smokers enrolled in an intravenous nicotine infusion study. Addictive Behaviors 2023, 140: 107615. PMID: 36640662, PMCID: PMC9911383, DOI: 10.1016/j.addbeh.2023.107615.Peer-Reviewed Original ResearchConceptsSmoking-related illnessesNegative drug effectsNicotine clearanceOvernight abstinenceNicotine infusionDrug effectsMentholated cigarettesWhite individualsBlack individualsAcute pharmacologic effectsSmoking-related morbiditySmoking-related diseasesAdministration of nicotineSmoking-related outcomesSubjective drug effectsShort-term abstinenceLower ratesTrend level differenceLarge racial disparitiesNicotine administrationNicotine dosesTrend-level significancePharmacologic effectsTreatment strategiesOutcome measures
2018
S142. A Predictive Approach to Identify Clinical State, Emotional Valence and Pharmacologic Effect in Human Task-Based fMRI Data
Barron D, Salehi M, Browning M, Harmer C, Constable T, Duff E. S142. A Predictive Approach to Identify Clinical State, Emotional Valence and Pharmacologic Effect in Human Task-Based fMRI Data. Biological Psychiatry 2018, 83: s403. DOI: 10.1016/j.biopsych.2018.02.1034.Peer-Reviewed Original Research
2016
First-in-Human Assessment of the Novel PDE2A PET Radiotracer 18F-PF-05270430
Naganawa M, Waterhouse RN, Nabulsi N, Lin SF, Labaree D, Ropchan J, Tarabar S, DeMartinis N, Ogden A, Banerjee A, Huang Y, Carson RE. First-in-Human Assessment of the Novel PDE2A PET Radiotracer 18F-PF-05270430. Journal Of Nuclear Medicine 2016, 57: 1388-1395. PMID: 27103022, PMCID: PMC5093918, DOI: 10.2967/jnumed.115.166850.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAzabicyclo CompoundsAzetidinesBrainComputer SimulationCyclic Nucleotide Phosphodiesterases, Type 2Feasibility StudiesFemaleHumansIsotope LabelingMacaca mulattaMaleMetabolic Clearance RateModels, BiologicalMolecular ImagingOrgan SpecificityPilot ProjectsPositron-Emission TomographyRadiopharmaceuticalsReproducibility of ResultsSensitivity and SpecificityTissue DistributionConceptsTest-retest variabilityHuman studiesPET ligandWhite matterNeocortical regionsMultilinear analysis 1MSv/MBqHealthy male subjectsDetectable pharmacologic effectsAppropriate tracer kinetic modelsTest-retest protocolAdverse eventsBrain uptakePharmacologic effectsRegional time-activity curvesTarget doseTime-activity curvesTracer uptakeMale subjectsWhole brainBrain regionsEffective doseCritical organsPET radiotracersNonhuman primates
2013
Urocortin 2 autocrine/paracrine and pharmacologic effects to activate AMP-activated protein kinase in the heart
Li J, Qi D, Cheng H, Hu X, Miller EJ, Wu X, Russell KS, Mikush N, Zhang J, Xiao L, Sherwin RS, Young LH. Urocortin 2 autocrine/paracrine and pharmacologic effects to activate AMP-activated protein kinase in the heart. Proceedings Of The National Academy Of Sciences Of The United States Of America 2013, 110: 16133-16138. PMID: 24043794, PMCID: PMC3791748, DOI: 10.1073/pnas.1312775110.Peer-Reviewed Original ResearchMeSH KeywordsAcetyl-CoA CarboxylaseAMP-Activated Protein KinasesAnalysis of VarianceAnimalsAntibodies, NeutralizingCorticotropin-Releasing HormoneEnzyme ActivationImmunoblottingImmunohistochemistryMiceMyocardiumPeptide FragmentsPhosphorylationReceptors, Corticotropin-Releasing HormoneReperfusion InjurySignal TransductionUrocortinsConceptsIschemia/reperfusionIschemia/reperfusion injuryUCN2 treatmentReperfusion injuryContractile dysfunctionRegional ischemia/reperfusionAMPK activationHeart muscleIschemic AMPK activationAutocrine/paracrine pathwayCardiac contractile dysfunctionAutocrine/paracrine factorCorticotropin-releasing factor (CRF) familyIsolated heart muscleCRFR2 antagonistAcetyl-CoA carboxylase phosphorylationCardiac damageMyocardial injuryCRF receptorsPharmacologic effectsUrocortin 2ΕV1-2Activation of AMPParacrine pathwaysReperfusion
2012
Sex differences in stimulus expectancy and pharmacologic effects of a moderate dose of alcohol on smoking lapse risk in a laboratory analogue study
Kahler CW, Metrik J, Spillane NS, Leventhal AM, McKee SA, Tidey JW, McGeary JE, Knopik VS, Rohsenow DJ. Sex differences in stimulus expectancy and pharmacologic effects of a moderate dose of alcohol on smoking lapse risk in a laboratory analogue study. Psychopharmacology 2012, 222: 71-80. PMID: 22227611, PMCID: PMC3687530, DOI: 10.1007/s00213-011-2624-6.Peer-Reviewed Original ResearchConceptsInstruction conditionPharmacologic effectsStimulus expectancyQuit smoking attemptsDirect pharmacologic effectInitial lapseHeavy alcohol drinkersLapse riskLaboratory analog studiesPlacebo designBeverage contentSmoking attemptsAnalogue studyAlcohol drinkersGreater satisfactionModerate doseSex differencesSmoking behaviorPharmacological effectsSmokingNonalcoholic beveragesTaskCondition effectsSatisfactionInstruction
2011
Neurologic Prognosis in Cardiac Arrest Patients Treated With Therapeutic Hypothermia
Blondin NA, Greer DM. Neurologic Prognosis in Cardiac Arrest Patients Treated With Therapeutic Hypothermia. The Neurologist 2011, 17: 241-248. PMID: 21881465, DOI: 10.1097/nrl.0b013e318224ee0e.Peer-Reviewed Original ResearchConceptsTherapeutic hypothermiaCardiac arrestNeurologic prognosisNeurologic outcomeGood neurologic outcomeCardiac arrest patientsNeurology practice parameterNeuromuscular blocking agentsCerebrospinal fluid biomarkersEligible patientsNeurologic prognosticationNeurophysiologic testingArrest patientsNeurophysiologic findingsPoor prognosisClinical examinationFluid biomarkersPharmacologic effectsBlocking agentPhysiologic effectsPractice parametersClinical examBetter outcomesPatientsPrognosisIntravenous Ethanol Infusion Decreases Human Cortical γ-Aminobutyric Acid and N-Acetylaspartate as Measured with Proton Magnetic Resonance Spectroscopy at 4 Tesla
Gomez R, Behar KL, Watzl J, Weinzimer SA, Gulanski B, Sanacora G, Koretski J, Guidone E, Jiang L, Petrakis IL, Pittman B, Krystal JH, Mason GF. Intravenous Ethanol Infusion Decreases Human Cortical γ-Aminobutyric Acid and N-Acetylaspartate as Measured with Proton Magnetic Resonance Spectroscopy at 4 Tesla. Biological Psychiatry 2011, 71: 239-246. PMID: 21855054, PMCID: PMC3227760, DOI: 10.1016/j.biopsych.2011.06.026.Peer-Reviewed Original ResearchConceptsIntravenous ethanol infusionProton magnetic resonance spectroscopyEthanol infusionNAA levelsN-acetylaspartateCortical γ-aminobutyric acidAcute pharmacologic effectsLevels of GABAHealthy social drinkersBreath alcohol levelsN-acetylaspartyl-glutamateCortical GABAEthanol modulatesFirst infusionΓ-aminobutyric acidGABA levelsPharmacologic effectsBrain ethanolOccipital GABAInfusionAlcohol levelsMagnetic resonance spectroscopyReceptor functionBreath ethanolHuman cortex
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply